A phase 2 multicenter randomized double-blind placebo-controlled study to assess the efficacy safety and tolerability of AVP-786 (deudextromethorphan hydrobromide [D6-DM]/ quinidine sulfate [Q]) for the treatment of neurobehavioral disinhibition including aggression agitation and irritability in patients with traumatic brain injury (TBI).
-
- STATUS
- None
Updated on 19 February 2024
Summary
Traumatic brain injury (TBI) is a common medical condition with serious and long term sequelae that impact patients ability to function. The neurological insult may induce marked behavioral changes, such as aggression, agitation, and irritability. This behavior is severely destructive to patients and their caregivers. This study is assessing the efficacy of AVP-786 as a serotonin reuptake inhibitor. It is hypothesized that this drug may contribute to treating neurobehavioral disinhibition after TBI.
Details
| Condition | TBD, tbd, tbd |
|---|---|
| Age | 99years or below |
| Clinical Study Identifier | TBD |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.